EVALUATION OF DEMOGRAPHIC, CLINIC AND GENETIC CHARACTERISTICS OF PATIENTS ADMITTED TO TRAKYA UNIVERSITY HOSPITAL WITH HYPERTROPHIC CARDIOMYOPATHY

Abstract

Aims: This study aims to evaluate the genetics, clinical characteristics, and functional abnormalities of patients diagnosed with hypertrophic cardiomyopathy in Trakya University Hospital. Methods: This retrospective study was conducted with patients who were diagnosed with hypertrophic cardiomyopathy between November 2009 - November 2019 in Trakya University Hospital. The data were obtained from the hospital’s database. Patients’ data (regarding age, gender, ge- netics, transthoracic echocardiogram findings, medications, types of hypertrophic cardiomyopathy, and first diagnoses) were examined. Numbers, percentages, means, and standard deviations were used as descriptive statistics. Results: Eleven patients with hypertrophic cardiomyopathy were evaluated. Five (45.45%) were female and 6 (54.54%) were male. The mean age of the female patients was 58.20 ± 8.57 years. The most common type of hypertrophic cardiomyopathy was found to be asymmetrical septal cardiomyopathy [7 (63.63%)]. Three (27.27%) patients presented with hypertension. There were gene mutations in three patients. Among these three patients, two (18.18%) patients have MYBPC3, and one (9.09%) patient has TTN gene mutations. Conclusion: Hypertrophic car- diomyopathy is usually accompanied by comorbidities such as arrhythmias, myocardial infarction, coronary artery disease. Therefore, these patients must be paid attention to in these matters.

Keywords

• Hypertrophic cardiomyopathy
• hypertension
• sudden cardiac death

References

1. 1. Sabater-Molina M, Pérez-Sánchez I, Hernández Del Rincón JP et al. Genetics of hypertrophic cardiomyopathy: a review of current state. Clin Genet 2018;93(1):3- 14.
2. 2. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013;381(9862):242- 55.
3. 3. Cruickshank S. Cardiomyopathy. Nurs Stand 2004;18(23):46-56.
4. 4. Teekakirikul P, Zhu W, Huang HC et al. Hypertrophic cardiomyopathy: an over- view of genetics and management. Biomolecules 2019;9(12):878.
5. 5. Wigle ED, The diagnosis of hypertrohic cardiomyopatyh. Heart 2001;86(6):709- 14.
6. 6. Hensley N, Dietrich J, Nyhan D et al. M. Hypertrophic cardiomyopathy: a review. Anesth Analg 2015;120(3):554-69.
7. 7. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121(7):749-70.
8. 8. Shah M. Hypertrophic cardiomyopathy. Cardiol Young 2017;27(S1):25-30.

9. 9. Noureldin RA, Liu S, Nacif MS et al. The diagnosis of hypertrophic cardio- myopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14(1):17.
10. 10. van Velzen HG, Schinkel AFL, Baart SJ et al. Effect of gender and genetic muta- tions on outcomes in patients with hypertrophic cardiomyopathy. Am J Cardiol 2018;122(11):1947-54.
11. 11. Olivotto I, Maron MS, Adabag AS et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46(3):480-7.
12. 12. Brown NJ, Vaughan DE. Angiotensin converting enzyme inhibitors. Circulation 1990;97(14):1411-20.
13. 13. Cordonnier DJ, Zaoui P, Halimi S. Role of ACE inhibitors in patients with diabe- tes mellitus. Drugs 2001;61(13):1883-92.
14. 14. Deng T, Ou B, Zhu T et al. The effect of hypertension on cardiac structure and function in different types of hypertrophic cardiomyopathy: a single-center retro- spective study. Clin Exp Hypertens 2019;41(4):359-65.
15. 15. Papadopoulos DP, Papademetriou V. Hypertrophic and hypertensive hypertro- phic cardiomyopathy--a true association? Angiology 2010;61(1):92-9.
16. 16. Teenkakirikul P, Zhu W, Huang HC et al. Hypertrophic cardiomyopathy; an over- view of genetics and management. Biomolecules 2019;19(9):878.
17. 17. Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagno- sis strategy. Circulation 2003;107(17):2227-32.
18. 18. Yacoub MH, El-Hamamsy I, Said K et al. The left ventricular outflow in hyper- trophic cardiomyopathy: from structure to function. J Cardiovasc Transl Res 2009;2(4):510-7.
19. 19. Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348(4):295-303.
20. 20. Lee MS, Chen CH. Myocardial bridging: an up-to-date review. J Invasive Cardiol 2015;27(11):521-8.
21. 21. Raphael CE, Cooper R, Parker KH et al. Mechanism of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnet- ic resonance. J Am Coll Cardiol 2016;68(15):1651-60.
22. 22. Maclntyre C, Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 2016;133(19):1901-5.